Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derive
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
What it measured
Main measures
Safety (adverse events)
Four year follow-up
Safety
Other measures (1)
Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)
Four year follow-up
Disability progression
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
* Diagnosis of Multiple Sclerosis * Understanding and willingness to sign a written informed consent document
Exclusion criteria
* Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of multiple sclerosis
Papers
Background
Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014 Mar 25;14:58. doi: 10.1186/1471-2377-14-58.Background
Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020 Dec 1;143(12):3574-3588. doi: 10.1093/brain/awaa333.Background
Riordan NH, Morales I, Fernandez G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018 Mar 9;16(1):57. doi: 10.1186/s12967-018-1433-7.Background
Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, Zhang YZ, Lou JY, Cao B, Wang YL. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23 Suppl 1:S113-22. doi: 10.3727/096368914X685005. Epub 2014 Nov 5.
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory
Phase 1 · Not yet recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous System Autoimm
Phase 1 · Not yet recruiting
Still running
- Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimm
Phase 1 · Withdrawn
Stopped
- Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases
Early phase 1 · Not yet recruiting
Still running
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory
Phase 1 · Recruiting
Still running
- Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoi
Status unknown
No results found
History
Started
Jun 2021
Main results due
Oct 2028
Finished
Oct 2028